MAP2K7 and esophageal squamous cell carcinoma: Based upon these results showing the potential joint efficacy of MEK and EGFR blockade and the role of ERK reactivation in response to EGFR inhibition in ESCC, we next tested whether addition of MEK inhibition could prevent or delay the emergence of acquired resistance in OE21 and KYSE140 cells when treated with EGFR inhibitors.